Advances in Liquid Biopsy Using Circulating Tumor Cells and Circulating Cell-free Tumor DNA for Detection and Monitoring of Breast Cancer

Overview

Journal Clin Exp Med

Specialty General Medicine

Date 2019 Jun 14

PMID 31190187

Citations 16

Authors

Xiaofen Zhang

Shaoqing Ju

Xudong Wang

Hui Cong

Affiliations

Soon will be listed here.

Abstract

Overview the progress of liquid biopsy using circulating tumor cells (CTCs) and circulating cell-free tumor DNA (cfDNA) to detect and monitor breast cancer. Based on numerous research efforts, the potential value of CTCs and cfDNA in the clinical aspects of cancer has become clear. With the development of next-generation sequencing analysis and newly developed technologies, many technical issues have been resolved, making liquid biopsy widely used in clinical practice. They can be powerful tools for dynamic monitoring of tumor progression and therapeutic efficacy. In the field of breast cancer, liquid biopsy is a research hot spot in recent years, playing a key role in monitoring breast cancer metastasis, predicting disease recurrence and assessing clinical drug resistance. Liquid biopsy has the advantages of noninvasive, high sensitivity, high specificity and real-time dynamic monitoring. Still application is far from reality, but the research and application prospects of CTCs and cfDNA in breast cancer are still worth exploring and discovering. This article reviews the main techniques and applications of CTCs and cfDNA in breast cancer.

Citing Articles

Identification of circulating tumor cells captured by the FDA-cleared Parsortix PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations.

Ciccioli M, Kim K, Khazan N, Khoury J, Cooke M, Miller M J Exp Clin Cancer Res. 2024; 43(1):240.

PMID: 39169412 PMC: 11337573. DOI: 10.1186/s13046-024-03149-x.

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.

Carrasco R, Ingelmo-Torres M, Trullas R, Roldan F, Rodriguez-Carunchio L, Juez L Int J Mol Sci. 2023; 24(23).

PMID: 38068899 PMC: 10706140. DOI: 10.3390/ijms242316578.

Chemically-Modified Sepharose 6B Beads for Collection of Circulating Tumor Cells.

Chen H, Zhang Y, Ma X, Zhou B, Liu Z Biomolecules. 2023; 13(7).

PMID: 37509107 PMC: 10377418. DOI: 10.3390/biom13071071.

Circulating tumor DNA sequencing of pediatric solid and brain tumor patients: An institutional feasibility study.

Mangum R, Reuther J, Sen Baksi K, Gandhi I, Zabriskie R, Recinos A Pediatr Hematol Oncol. 2023; 40(8):719-738.

PMID: 37366551 PMC: 10592361. DOI: 10.1080/08880018.2023.2228837.

Integrative, In Silico and Comparative Analysis of Breast Cancer Secretome Highlights Invasive-Ductal-Carcinoma-Grade Progression Biomarkers.

Kastora S, Kounidas G, Speirs V, Masannat Y Cancers (Basel). 2022; 14(16).

PMID: 36010848 PMC: 9406168. DOI: 10.3390/cancers14163854.

References

Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer F, Hesch R . DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001; 61(4):1659-65. View

Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R . Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002; 49(4):150-8. DOI: 10.1002/cyto.10161. View

Sozzi G, Conte D, Leon M, Ciricione R, Roz L, Ratcliffe C . Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003; 21(21):3902-8. DOI: 10.1200/JCO.2003.02.006. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Atamaniuk J, Vidotto C, Tschan H, Bachl N, Stuhlmeier K, Muller M . Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin Chem. 2004; 50(9):1668-70. DOI: 10.1373/clinchem.2004.034553. View

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Cristofanilli M, Hayes D, Budd G, Ellis M, Stopeck A, Reuben J . Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005; 23(7):1420-30. DOI: 10.1200/JCO.2005.08.140. View

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

Kirsch C, Weickmann S, Schmidt B, Fleischhacker M . An improved method for the isolation of free-circulating plasma DNA and cell-free DNA from other body fluids. Ann N Y Acad Sci. 2008; 1137:135-9. DOI: 10.1196/annals.1448.035. View

10.

Mostert B, Sleijfer S, Foekens J, Gratama J . Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev. 2009; 35(5):463-74. DOI: 10.1016/j.ctrv.2009.03.004. View

11.

Jain R, Duda D, Willett C, Sahani D, Zhu A, Loeffler J . Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009; 6(6):327-38. PMC: 3057433. DOI: 10.1038/nrclinonc.2009.63. View

12.

Kim C, Paik S . Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010; 7(6):340-7. DOI: 10.1038/nrclinonc.2010.61. View

13.

Aktas B, Muller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg C . Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol. 2011; 122(2):356-60. DOI: 10.1016/j.ygyno.2011.04.039. View

14.

Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson E, Noel A . A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer. Oncogene. 2011; 31(33):3741-53. DOI: 10.1038/onc.2011.540. View

15.

Ksiazkiewicz M, Markiewicz A, Zaczek A . Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 2012; 79(4):195-208. DOI: 10.1159/000337106. View

16.

Breitbach S, Tug S, Simon P . Circulating cell-free DNA: an up-coming molecular marker in exercise physiology. Sports Med. 2012; 42(7):565-86. DOI: 10.2165/11631380-000000000-00000. View

17.

Bednarz-Knoll N, Alix-Panabieres C, Pantel K . Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev. 2012; 31(3-4):673-87. DOI: 10.1007/s10555-012-9370-z. View

18.

Zhang L, Ridgway L, Wetzel M, Ngo J, Yin W, Kumar D . The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med. 2013; 5(180):180ra48. PMC: 3863909. DOI: 10.1126/scitranslmed.3005109. View

19.

Dawson S, Rosenfeld N, Caldas C . Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 369(1):93-4. DOI: 10.1056/NEJMc1306040. View

20.

Elshimali Y, Khaddour H, Sarkissyan M, Wu Y, Vadgama J . The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013; 14(9):18925-58. PMC: 3794814. DOI: 10.3390/ijms140918925. View